SPF Technologies
Research - Boston, Massachusetts, United States
SPF Technologies Employees
SPF Technologies Details
SPF is a privately held company developing bioprocessing and bioanalytical devices and applications to meet manufacturing and sample-prep needs of biopharmaceutical companies, life science researchers, and drug development scientists. We develop new concepts—devices and processes—that make a real difference to end-users by providing new capabilities and streamlining manufacturing and laboratory processes.Some of our products:VacuCon™ The VacuCon™ Concentrator offers simple and fast ultrafiltration concentration of samples greater than 50mL. The first-generation device can quickly concentrate 20–100mL to very high concentration factors, up to 100-fold. All you need to operate the VacuCon™ concentrator is a conventional vacuum source!Walk-away operation means that once you add your sample to the feed reservoir and vacuum is connected, you can walk away from the concentrator – the device self-primes and terminates permeation automatically, releasing you from having to constantly observe the concentration process. When you return to the device, just disconnect the vacuum and recover the retentate fraction or concentrate into a syringe. Chromassette® Chromassette® devices are chromatography columns in the form of a cassette. It is the first practical modular chromatography platform, offering truly linear scale-up, which until now has been an elusive property desired by anyone practicing chromatography.Chromassette® devices are further characterized by a bed-supporting structure that prevents the compression of chromatographic beads even at high velocities exceeding 1000 cm/hr.The Chromassette® Technology is exclusively licensed to JSR Corporation for Biopharmaceutical Processing. If you are want to learn more about the technology for biopharm processes contact JSR Corporation or go to the Chromassette webpage in JSR Life Sciences. Single-Pass Tangential-Flow Filtration (SP-TFF™) was invented here and has become a best practice in the biopharm industry.
